http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102579452-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9145b4ea6b26eefdf1efb3af51673f85 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate | 2012-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47116d5de1c006e073251cae1f147ce8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8554d6d4927da9f09645776c34790459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_316a54fc6c321e2988fc4f61e651798a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5ac990453f573a0cea85e6868e03412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66098252e88580141a2c095cb5961254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cba2aabd470a7eb57af75b3152b750c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_122eb7d5cfe2a0996d5124cf5e397533 |
| publicationDate | 2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102579452-B |
| titleOfInvention | Preparation method of tryptanthrin compound and new application of tryptanthrin compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor |
| abstract | The invention relates to a preparation method of tryptanthrin compound and a new application of tryptanthrin compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor, in particular to an application of tryptanthrin compound in preparing IDO inhibitor and in preparing medicine for preventing and/or treating diseases having pathological characteristics of tryptophan metabolic disturbance mediated by IDO. The structure of the tryptanthrin compound is shown in formula A in the description, wherein R1 and R2 are respectively and independently selected from hydrogen, nitryl, C1 to C5 alkyl, halogen or piperazinyl. The tryptanthrin compound can be used as an IDO inhibitor with high activity and is used for treating diseases having pathological characteristics of tryptophan metabolic disturbance mediated by IDO such as tumor, cancer, Alzheimer disease, autoimmune disease, cataract, mental block, tristimania, anxiety neurosis, acquired immure deficiency syndrome (AIDS) and other serious diseases, and as a medicinal resource which is very difficult to get, the tryptanthrin compound has good potential on researching and developing new medicine. |
| priorityDate | 2012-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 317.